Literature DB >> 34785577

Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy.

Noemi Andor1, Philipp M Altrock1,2, Navami Jain1,3, Ana P Gomes4.   

Abstract

Tetraploidy is an aneuploidy-permissive condition that can fuel tumorgenesis. The tip-over hypothesis of cytotoxic therapy sensitivity proposes that therapy is effective if it pushes a cell's aneuploidy above a viable tipping point. But elevated aneuploidy alone may not account for this tipping point. Tissue microenvironments that lack sufficient resources to support tetraploid cells can explain the fitness cost of aneuploidy. Raw materials needed to generate deoxynucleotides, the building blocks of DNA, are candidate rate-limiting factors for the evolution of high-ploidy cancer cells. Understanding the resource cost of high ploidy is key to uncover its therapeutic vulnerabilities across tissue sites with versatile energy supplies. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 34785577      PMCID: PMC8898264          DOI: 10.1158/0008-5472.CAN-21-2794

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  75 in total

1.  Masking and purging mutations following EMS treatment in haploid, diploid and tetraploid yeast (Saccharomyces cerevisiae).

Authors:  B K Mable; S P Otto
Journal:  Genet Res       Date:  2001-02       Impact factor: 1.588

2.  Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma.

Authors:  A T Look; F A Hayes; R Nitschke; N B McWilliams; A A Green
Journal:  N Engl J Med       Date:  1984-07-26       Impact factor: 91.245

3.  DNA damage response activates respiration and thereby enlarges dNTP pools to promote cell survival in budding yeast.

Authors:  Pengli Bu; Shreya Nagar; Madhura Bhagwat; Pritpal Kaur; Ankita Shah; Joey Zeng; Ivana Vancurova; Ales Vancura
Journal:  J Biol Chem       Date:  2019-05-09       Impact factor: 5.157

4.  Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia.

Authors:  K Chimploy; M L Tassotto; C K Mathews
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

5.  Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells.

Authors:  Takeshi Fujiwara; Madhavi Bandi; Masayuki Nitta; Elena V Ivanova; Roderick T Bronson; David Pellman
Journal:  Nature       Date:  2005-10-13       Impact factor: 49.962

Review 6.  Genomic Instability in Cancer: Teetering on the Limit of Tolerance.

Authors:  Noemi Andor; Carlo C Maley; Hanlee P Ji
Journal:  Cancer Res       Date:  2017-04-21       Impact factor: 12.701

7.  Near-tetraploid cancer cells show chromosome instability triggered by replication stress and exhibit enhanced invasiveness.

Authors:  Darawalee Wangsa; Isabel Quintanilla; Keyvan Torabi; Maria Vila-Casadesús; Amaia Ercilla; Gregory Klus; Zeynep Yuce; Claudia Galofré; Miriam Cuatrecasas; Juan José Lozano; Neus Agell; Daniela Cimini; Antoni Castells; Thomas Ried; Jordi Camps
Journal:  FASEB J       Date:  2018-02-08       Impact factor: 5.191

8.  Interstitial Inorganic Phosphate as a Tumor Microenvironment Marker for Tumor Progression.

Authors:  Andrey A Bobko; Timothy D Eubank; Benoit Driesschaert; Ilirian Dhimitruka; Jason Evans; Rahman Mohammad; Elena E Tchekneva; Mikhail M Dikov; Valery V Khramtsov
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

9.  Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation.

Authors:  Yang Zhang; Yi Xu; Wenyun Lu; Jonathan M Ghergurovich; Lili Guo; Ian A Blair; Joshua D Rabinowitz; Xiaolu Yang
Journal:  Cell Metab       Date:  2020-11-06       Impact factor: 27.287

Review 10.  Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy.

Authors:  Nazmul Haque; Mohammad Tariqur Rahman; Noor Hayaty Abu Kasim; Aied Mohammed Alabsi
Journal:  ScientificWorldJournal       Date:  2013-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.